信達生物(01801.HK):達伯坦用於治療局部晚期或轉移性膽管癌獲台批准
信達生物(01801.HK)公布,達伯坦(pemigatinib)正式獲得台灣地區衛生福利部食品藥物管理署批准,用於治療成人接受過全身性藥物治療、腫瘤具有成纖維細胞生長因子受體2(「FGFR2」)融合或重排、不可手術切除的局部晚期或轉移性膽管癌。
達伯坦(由Incyte和信達生物共同開發,信達生物負責內地、香港、澳門和台灣地區的商業化)這是是首個在台灣地區獲批的治療膽道惡性腫瘤的酪氨酸激(酉每)抑制劑。這是信達生物獲批的第一款小分子藥產品,也是信達生物第五款獲批上市的創新藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.